Rocio Alvarez
YOU?
Author Swipe
View article: Constitutional MLH1 Methylation Is a Major Contributor to Mismatch Repair–Deficient, MLH1-Methylated Colorectal Cancer in Patients Aged 55 Years and Younger
Constitutional MLH1 Methylation Is a Major Contributor to Mismatch Repair–Deficient, MLH1-Methylated Colorectal Cancer in Patients Aged 55 Years and Younger Open
Background: Most mismatch repair–deficient (MMRd) colorectal cancer (CRC) cases arise sporadically, associated with somatic MLH1 methylation, whereas approximately 20% have germline mismatch repair pathogenic variants causing Lynch syndrom…
View article: POLE-Mutant Colon Cancer Treated with PD-1 Blockade Showing Clearance of Circulating Tumor DNA and Prolonged Disease-Free Interval
POLE-Mutant Colon Cancer Treated with PD-1 Blockade Showing Clearance of Circulating Tumor DNA and Prolonged Disease-Free Interval Open
Colon cancer with high microsatellite instability is characterized by a high tumor mutational burden and responds well to immunotherapy. Mutations in polymerase ɛ, a DNA polymerase involved in DNA replication and repair, are also associate…
View article: Supplementary Figure 2 from Off-Target Effects of c-MET Inhibitors on Thyroid Cancer Cells
Supplementary Figure 2 from Off-Target Effects of c-MET Inhibitors on Thyroid Cancer Cells Open
PDF - 3009KB, Effect of Tivantinib and Crizotinib on cell growth and c-MET phosphorylation of MDA-MB-231 and HT29 cells.
View article: Supplementary Figure 1 from Off-Target Effects of c-MET Inhibitors on Thyroid Cancer Cells
Supplementary Figure 1 from Off-Target Effects of c-MET Inhibitors on Thyroid Cancer Cells Open
PDF - 3892KB, Molecular structure of Cizotinib, Tivantinib, and SU11274.
View article: Data from Off-Target Effects of c-MET Inhibitors on Thyroid Cancer Cells
Data from Off-Target Effects of c-MET Inhibitors on Thyroid Cancer Cells Open
Aberrantly activated c-MET signaling occurs in several cancers, promoting the development of c-MET inhibitors. In this study, we found that eight of eight thyroid cancer cell lines (including six anaplastic thyroid cell lines) have promine…
View article: Supplementary Figure 2 from Off-Target Effects of c-MET Inhibitors on Thyroid Cancer Cells
Supplementary Figure 2 from Off-Target Effects of c-MET Inhibitors on Thyroid Cancer Cells Open
PDF - 3009KB, Effect of Tivantinib and Crizotinib on cell growth and c-MET phosphorylation of MDA-MB-231 and HT29 cells.
View article: Supplementary Table 1 from Off-Target Effects of c-MET Inhibitors on Thyroid Cancer Cells
Supplementary Table 1 from Off-Target Effects of c-MET Inhibitors on Thyroid Cancer Cells Open
PDF - 60KB, Antibodies for Western blotting.
View article: Supplementary Figure 1 from Off-Target Effects of c-MET Inhibitors on Thyroid Cancer Cells
Supplementary Figure 1 from Off-Target Effects of c-MET Inhibitors on Thyroid Cancer Cells Open
PDF - 3892KB, Molecular structure of Cizotinib, Tivantinib, and SU11274.
View article: Supplementary Table 1 from Off-Target Effects of c-MET Inhibitors on Thyroid Cancer Cells
Supplementary Table 1 from Off-Target Effects of c-MET Inhibitors on Thyroid Cancer Cells Open
PDF - 60KB, Antibodies for Western blotting.
View article: Data from Off-Target Effects of c-MET Inhibitors on Thyroid Cancer Cells
Data from Off-Target Effects of c-MET Inhibitors on Thyroid Cancer Cells Open
Aberrantly activated c-MET signaling occurs in several cancers, promoting the development of c-MET inhibitors. In this study, we found that eight of eight thyroid cancer cell lines (including six anaplastic thyroid cell lines) have promine…
View article: Large Cancer Pedigree Involving Multiple Cancer Genes including Likely Digenic MSH2 and MSH6 Lynch Syndrome (LS) and an Instance of Recombinational Rescue from LS
Large Cancer Pedigree Involving Multiple Cancer Genes including Likely Digenic MSH2 and MSH6 Lynch Syndrome (LS) and an Instance of Recombinational Rescue from LS Open
Lynch syndrome (LS), caused by heterozygous pathogenic variants affecting one of the mismatch repair (MMR) genes (MSH2, MLH1, MSH6, PMS2), confers moderate to high risks for colorectal, endometrial, and other cancers. We describe a four-ge…
View article: Circulating tumor DNA dynamics and response to immunotherapy in colorectal cancer
Circulating tumor DNA dynamics and response to immunotherapy in colorectal cancer Open
Circulating tumor DNA (ctDNA) is increasingly being investigated as a tool to detect minimal residual disease in resected, stage I-III colorectal cancer. Recent ctDNA studies have indicated that detection of ctDNA following surgery for res…
View article: Methylated Septin9 (m<i>SEPT9</i>): A Promising Blood-Based Biomarker for the Detection and Screening of Early-Onset Colorectal Cancer
Methylated Septin9 (m<i>SEPT9</i>): A Promising Blood-Based Biomarker for the Detection and Screening of Early-Onset Colorectal Cancer Open
Early-onset colorectal cancer (EOCRC), defined as a diagnosis under age 50, is an emerging public health burden. As many of these individuals fall outside of screening guidelines, the development of a minimally invasive, accurate screening…
View article: T cell protein tyrosine phosphatase protects intestinal barrier function by restricting epithelial tight junction remodeling
T cell protein tyrosine phosphatase protects intestinal barrier function by restricting epithelial tight junction remodeling Open
Genome-wide association studies revealed that loss-of-function mutations in protein tyrosine phosphatase non-receptor type 2 (PTPN2) increase the risk of developing chronic immune diseases, such as inflammatory bowel disease (IBD) and celi…
View article: A Simulated Microgravity Environment Causes a Sustained Defect in Epithelial Barrier Function
A Simulated Microgravity Environment Causes a Sustained Defect in Epithelial Barrier Function Open
Intestinal epithelial cell (IEC) junctions constitute a robust barrier to invasion by viruses, bacteria and exposure to ingested agents. Previous studies showed that microgravity compromises the human immune system and increases enteropath…
View article: The Autoimmune Susceptibility Gene, <i>PTPN2</i>, Restricts Expansion of a Novel Mouse Adherent-Invasive <i>E. coli</i>
The Autoimmune Susceptibility Gene, <i>PTPN2</i>, Restricts Expansion of a Novel Mouse Adherent-Invasive <i>E. coli</i> Open
Inflammatory bowel diseases (IBD) involve genetic and environmental factors that play major roles in disease pathogenesis. Loss-of-function single-nucleotide polymorphisms (SNPs) in the protein tyrosine phosphatase non-receptor type 2 ( PT…
View article: Methylated <i>SEPTIN9</i> plasma test for colorectal cancer detection may be applicable to Lynch syndrome
Methylated <i>SEPTIN9</i> plasma test for colorectal cancer detection may be applicable to Lynch syndrome Open
Objective The plasma-based methylated SEPTIN9 (mSEPT9) is a colorectal cancer (CRC) screening test for adults aged 50–75 years who are at average risk for CRC and have refused colonoscopy or faecal-based screening tests. The applicability …
View article: Impact of Non-Toxic Metabolic Disruptors on Overall Survival and One Year Survival Rate in Exocrine Pancreatic Cancer. Update and Observations on Early Intervention
Impact of Non-Toxic Metabolic Disruptors on Overall Survival and One Year Survival Rate in Exocrine Pancreatic Cancer. Update and Observations on Early Intervention Open
Introduction: Despite the fact that exocrine pancreatic cancer ranks as one of the most lethal forms of neoplasm, with a mortality/incidence rate nearing 98% in both industrialized and developing countries, little improvements has been mad…
View article: P115 THE IBD CANDIDATE GENE, PTPN2, RESTRICTS INTESTINAL BARRIER DEFECTS AND CLAUDIN-2 EXPRESSION VIA STAT INHIBITION
P115 THE IBD CANDIDATE GENE, PTPN2, RESTRICTS INTESTINAL BARRIER DEFECTS AND CLAUDIN-2 EXPRESSION VIA STAT INHIBITION Open
Loss-of-function mutations in the protein tyrosine phosphatase non-receptor type 2 (PTPN2) gene locus increase IBD susceptibility. We reported that PTPN2 knockdown (PTPN2-KD) in intestinal epithelial cells (IECs): (i) increased IFN-g activ…